Japanese Maruho To Focus On Core Competence In Dermatology
This article was originally published in PharmAsia News
President of Osaka-based Maruho Co., a specialty dermatology, orthopedics and proctology drug maker, said the company will focus on becoming Japan's top pharmaceutical company in dermatology. According to Takagi, in order for Maruho, a company with ¥20 billion ($200.9 million) in sales to compete with Takeda with ¥100billion ($1.0 billion) in sales, a successful strategy is not becoming a mini-Takeda, but becoming a highly focused specialty pharmaceutical company. Since becoming president two years ago, Takagi has focused business on dermatology products, which accounts for Maruho's biggest sales. As a result of this strategy, Maruha's asteatosis cutis drugsHirudoid series have reached ¥10 billion ($100.4 million) in sales. (Click here for more - Japanese language
You may also be interested in...
Guardant’s CEO anticipates accelerated adoption and reimbursement of its FDA-approved liquid biopsy assay and more biopharma partnerships.
Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m.
Agency commissioner appeals to AMA audience to communicate message that FDA review decisions are based on good science.